Results 161 to 170 of about 3,069,445 (313)

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Exploring the ethical use of race in cancer research. [PDF]

Oncologist
Pierre KJ, Chalmers CD, Amechi C, Dickerson J, Lulseged D, Dixon MD, Pentz RD.   +6 more
europepmc   +1 more source

Correction to: Characterizing phenotypic abnormalities associated with high-risk individuals developing lung cancer using electronic health records from the All of Us researcher workbench

, 2022
Jie Na, Nansu Zong, Chen Wang, David E. Midthun, Yuan Luo, Ping Yang, Guoqian Jiang   +6 more
openalex   +2 more sources

Funding cancer research [PDF]

Nature Medicine, 1998
openaire   +2 more sources

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Bioinformatics Strategies in Breast Cancer Research. [PDF]

Biomolecules
Veneziano M, Savini I, Cortellesi E, Gasperi V, Gambacurta A, Catani MV.   +5 more
europepmc   +1 more source

CANCER RESEARCH

International Journal of Clinical Practice, 1953
openaire   +3 more sources

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Breast cancer: When do you stop reading the literature?

South African Journal of Science, 2016
Brenda Wingfield
doaj   +1 more source

RNA sequencing in ovarian cancer research: a comprehensive review. [PDF]

J Ovarian Res
Shen F, Li C, Li Y, Shen Y, Han F.
europepmc   +1 more source